Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use 

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the publication of an independent, researcher-led peer-reviewed study demonstrating the potential for individuals with chronic spinal cord injury to use a personal exoskeleton to perform everyday activities while standing in their homes.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.